Kestra Medical Technologies (KMTS) Could Be 31% Overvalued As Earnings And 2027 Guidance Land
Kestra Medical Technologies (KMTS) shares are in focus after the company paired detailed fiscal 2026 results with fresh 2027 revenue guidance and a new multi tranche term loan facility that reshapes its funding profile.
See our latest analysis for Kestra Medical Technologies.
Kestra Medical Technologies’ latest earnings, 2027 revenue guidance and new term loan arrived after a choppy stretch, with a 1-day share price return of 1.8% and a 7-day share price return that declined 8.2%. However, a 30-day share price return of 20.6% and 1-year total shareholder return of 60.4% point to momentum that has been building over a longer horizon.
If you want to see what else is attracting attention around medical technology and connected care, it is a good moment to scan 40 healthcare AI stocks.
After Kestra Medical Technologies’ sharp 1-year run and updated 2027 revenue outlook, the stock still trades below the average analyst target. This gap may indicate lingering caution among investors or potential room for the valuation to move closer to those expectations.
Most Popular Narrative: 31.3% Overvalued
Compared with Kestra Medical Technologies’ last close at $24.62, the most followed narrative fair value of $18.74 points to a clear valuation gap that centers on growth expectations, margins and future multiples.
Although Kestra is benefiting from rising awareness of out of hospital cardiac risk and broader WCD adoption, the need for formal clinical guideline updates to materially expand usage creates uncertainty around how quickly prescriptions can scale. This could temper revenue growth if guideline changes take longer than expected.
Want to see how a single growth assumption, a profit margin reset and a stretched future earnings multiple combine to justify that fair value? The full narrative breaks down the revenue ramp, profitability bridge and valuation math that sit behind this 31.3% overvaluation call.
Result: Fair Value of $18.74 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the case for Kestra Medical Technologies being overvalued could be challenged if wearable cardioverter defibrillators gain wider guideline support or if commercial expansion leads to better payer coverage and margins.
Find out about the key risks to this Kestra Medical Technologies narrative.
Next Steps
With mixed views on Kestra Medical Technologies’ valuation and outlook, it makes sense to move quickly, review the underlying data yourself and weigh both sides of the story using the 1 key reward and 1 important warning sign.
Looking for more investment ideas beyond Kestra Medical Technologies?
If you stop with Kestra Medical Technologies, you might miss other stocks that fit your goals. Take a moment to scan a few focused sets of ideas.
- Target companies that combine quality and attractive pricing by reviewing 47 high quality undervalued stocks, which may warrant a closer look before the crowd catches on.
- Strengthen the foundation of your portfolio by checking the solid balance sheet and fundamentals stocks screener (48 results) for businesses with healthier financial footing.
- Get ahead of the market by scanning the screener containing 20 high quality undiscovered gems that could sit off most investors’ radar today.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com